Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term fasting in neoadjuvant chemotherapy for breast cancer
NCT02379585Phase 2Terminated
- Sponsor
- Western Regional Medical Center
- Start
- Jan 2013
- Primary completion
- Aug 2015
- Countries
- 1
01
Overview
Phase 2, open-label trial in breast cancer (2 arms), sponsored by Western Regional Medical Center. Primary endpoint: Pathological Response Rate at 12 weeks. Started Jan 2013; status: terminated.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02379585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02379585.